Latest Articles about AEGR

CHMP Positive on Aegerion's Lojuxta - Analyst Blog

Zacks Equity Research — Tue, 04 Jun 2013 01:25:58 Z

Aegerion Pharmaceuticals, Inc. ( AEGR ) recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for Lojuxta (lomitapide). The company is looking

Loss at Aegerion Narrower Than Expected - Analyst Blog

Zacks Equity Research — Sat, 04 May 2013 00:29:09 Z

Aegerion Pharmaceuticals, Inc. ( AEGR ) reported first quarter 2013 net loss per share of 64 cents, narrower than the Zacks Consensus Estimate of a loss of 72 cents, but wider than the

Aegerion Incurs Wider Loss - Analyst Blog

Zacks Equity Research — Thu, 07 Mar 2013 23:14:01 Z

Aegerion Pharmaceuticals, Inc. ( AEGR ) reported fourth quarter 2012 net loss per share of 86 cents, wider than the Zacks Consensus Estimate of a loss of 62 cents and the year-ago loss of

Pre-Market Earnings Report for March 6, 2013 : SPLS, BF/B, AEO, TFM, BIG, AEGR, HOV, WD, TRK, QRE, WILN, MFB

NASDAQ.com News — Wed, 06 Mar 2013 02:00:03 Z

The following companies are expected to report earnings prior to market open on 03/06/2013. Visit our Earnings Calendar for a full list of expected earnings releases. Staples, Inc. ( SPLS

Bull doubles bet on Aegerion Pharma

David Russell — Fri, 15 Feb 2013 21:02:15 Z

One investor is upping the ante in Aegerion Pharmaceuticals, which has doubled since October. optionMONSTER's Heat Seeker monitoring system detected the purchase of 3,000 March 30 calls for

US Nod for ISIS/Sanofi's Kynamro - Analyst Blog

Zacks Equity Research — Thu, 31 Jan 2013 02:40:01 Z

The US Food and Drug Administration (FDA) recently approved Kynamro (mipomersen sodium) injection developed by Genzyme, a Sanofi company ( SNY ) and Isis Pharmaceuticals Inc. ( ISIS ).

Leverage is key to trade in Aegerion

David Russell — Fri, 18 Jan 2013 13:45:38 Z

One investor in Aegerion Pharmaceuticals apparently prefers to use the leverage of options rather than trade common stock. Our Heat Seeker monitoring system detected the purchase of 3,000

Aegerion Prices Stock Offering - Analyst Blog

Zacks Equity Research — Tue, 15 Jan 2013 02:32:01 Z

Aegerion Pharmaceuticals, Inc. ( AEGR ) recently provided more details on its public offering. The offering is expected to close on Jan 16, 2013. The total offer consists of approximately

Aegerion to Raise Funds - Analyst Blog

Zacks Equity Research — Fri, 11 Jan 2013 20:40:01 Z

Aegerion Pharmaceuticals, Inc. ( AEGR ) recently announced its intention to raise funds through the issuance of its common stock in an underwritten public offering. The funds raised through

Aegerion Upbeat About 2013 - Analyst Blog

Zacks Equity Research — Wed, 09 Jan 2013 04:15:01 Z

Aegerion Pharmaceuticals Inc. ( AEGR ) recently announced its 2013 guidance as the company prepares for the launch of Juxtapid, which gained US Food and Drug Administration (FDA) approval

FDA Approves Aegerion's Juxtapid - Analyst Blog

Zacks Equity Research — Thu, 27 Dec 2012 03:21:01 Z

The US Food and Drug Administration (FDA) recently approved Aegerion Pharmaceuticals ' ( AEGR ) Juxtapid (lomitapide) capsules. Juxtapid has been approved for the treatment of patients

CHMP Negative on Isis' Kynamro - Analyst Blog

Zacks Equity Research — Tue, 18 Dec 2012 03:12:01 Z

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recently did not recommend the approval of Isis Pharmaceuticals Inc. ( ISIS ) and partner

Aegerion bulls looking for more upside

David Russell — Mon, 17 Dec 2012 20:55:16 Z

Aegerion Pharmaceuticals has been powering higher, and one investor apparently thinks that the gains will continue. optionMONSTER's Heat Seeker monitoring program detected the purchase of

FDA Panel Backs Isis' Kynamro - Analyst Blog

Zacks Equity Research — Mon, 22 Oct 2012 22:15:01 Z

The US Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee recently voted in favor of approving Genzyme, a Sanofi ( SNY ) company, and partner Isis

Safety Issues Raised over ISIS' Drug - Analyst Blog

Zacks Equity Research — Thu, 18 Oct 2012 00:50:32 Z

In its briefing document, the US Food and Drug Administration (FDA) recently raised issues regarding the safety of Genzyme, a Sanofi ( SNY ) company, and partner Isis Pharmaceuticals Inc.